In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen

Antiviral Research
Jaqueline Souza CavalcantiLuís Fernando de Macedo Brígido

Abstract

Raltegravir is an integrase inhibitor (INI) licensed for clinical use and other INI are in advanced stage of development. Different resistance mutations in HIV integrase from patients using these antiretroviral drugs have been described and G148H/R/K, N155H and less frequently Y143C/H/R are considered major resistant mutations to raltegravir. Both Stanford Database and Geno2Pheno list F121Y as conferring intermediate resistance "in vitro" both to raltegravir and elvitegravir. We report for the first time the "in vivo" selection F121Y and evolution to Y143R in a 31years old male clade B HIV-1 infected patient failing a raltegravir-containing salvage regimen. Plasma samples nine months prior to raltegravir (RAL-Naïve) and at weeks 32, 40 and 88 after RAL-containing regimen were analyzed. Antiretroviral susceptibility was evaluated at Stanford and Geno2Pheno from sequences obtained with RT-PCR. After a Viral load at week 12 below 50 copies/mL, viremia raised at week 20 to 4.5log10. The emergence of F121Y was observed at week 32 and 40, alongside with L74I, T97A, Q137H and V151I. At week 88 F121Y was no longer detected, L74I and T97A were maintained and Y143R emerged. F121Y might be an alternative pathway to Y143R. Changing of RAL-...Continue Reading

References

Jul 25, 2008·The New England Journal of Medicine·Roy T SteigbigelUNKNOWN BENCHMRK Study Teams
Jul 25, 2008·The New England Journal of Medicine·David A CooperUNKNOWN BENCHMRK Study Teams
Aug 19, 2008·Journal of Virological Methods·Kristel Van LaethemAnne-Mieke Vandamme
Feb 18, 2009·The Journal of Antimicrobial Chemotherapy·Isabelle MaletAnne-Genevieve Marcelin
Mar 6, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Caroline Bittencourt PassaesMariza Gonçalves Morgado
Jul 21, 2009·Antiviral Research·Luis Menéndez-Arias
Nov 11, 2009·Antimicrobial Agents and Chemotherapy·Olivier DelelisJean-François Mouscadet
Apr 5, 2011·The Journal of Infectious Diseases·Jose-Luis BlancoRobert W Shafer
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane

❮ Previous
Next ❯

Citations

Dec 24, 2013·International Journal of Antimicrobial Agents·Jaqueline de Souza CavalcantiUNKNOWN São Paulo Salvage Workgroup
Apr 9, 2014·The Journal of Antimicrobial Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin
Nov 12, 2014·The Journal of Antimicrobial Chemotherapy·Jaqueline de Souza CavalcantiLuis Fernando de Macedo Brigido
Oct 23, 2012·Current Opinion in Infectious Diseases·Anna Maria GerettiFrancesca Ceccherini-Silberstein
Sep 26, 2019·Frontiers in Microbiology·Lucas de Almeida MachadoAna Carolina Ramos Guimarães
Aug 24, 2021·European Journal of Medicinal Chemistry·Yue WangRenhua Fan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.